Condition

Recurrent World Health Organization (WHO) Grade II Glioma (3)

Recurrent WHO Grade III Glioma (2)

Intracranial Neoplasm (1)

Low Grade Glioma (1)

Recurrent Glioblastoma (1)

WHO Grade II Glioma (1)

WHO Grade III Glioma (1)

Overall Status

Recruiting (3)

Phase

phase 1 (2)

phase 2 (1)

Sponsor

Susan Chang (1)

Thomas Hope (1)

University of California, San Francisco (1)

Collaborator

GE Healthcare (1)

Novartis Pharmaceuticals (1)

Pediatric Brain Tumor Foundation (1)

Phillips-Medisize (1)

Sigma-Aldrich (1)

The Lilabean Foundation for Pediatric Brain Cancer Research (1)

Intervention

everolimus (1)

f-18 fluoroethyltyrosine (fet) (1)

hyperpolarized carbon c 13 pyruvate (1)

magnetic resonance imaging (1)

magnetic resonance spectroscopic imaging (1)

positron emission tomography (pet) (1)

trametinib (1)

Study Documents

Intervention Type

drug (3)

procedure (2)

Funder Type

Other (3)

Study Type

Interventional (3)

recurrent world health organization (who) grade ii glioma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma Trial in San

Recruiting

Recurrent World Health Organization (WHO) Grade II Glioma
+3 more

Hyperpolarized Carbon C 13 Pyruvate
+2 more

San Francisco, California

University of California, San Francisco

Dec 21, 2022

Intracranial Tumor, Low Grade Glioma, Recurrent Glioblastoma Trial in San Francisco (F-18 Fluoroethyltyrosine (FET), Positron

Recruiting

Intracranial Neoplasm
+4 more

F-18 Fluoroethyltyrosine (FET)
Positron Emission Tomography (PET)

San Francisco, California

University of California, San Francisco

Nov 7, 2022

Recurrent World Health Organization (WHO) Grade II Glioma Trial in United States (Everolimus, Trametinib)

Recruiting

Recurrent World Health Organization (WHO) Grade II Glioma

Birmingham, Alabama
+11 more

May 6, 2022